Skip to Content

The CEO of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) has sold $1,339,311.34 in stock.

The CEO of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) has sold $1,339,311.34 in stock.

On January 5, Thomas A. Mccourt, Chief Executive Officer of Ironwood Pharmaceuticals, Inc., sold 110,962 shares. Ironwood Pharmaceuticals, Inc. Ironwood Pharmaceuticals, Inc. is publicly traded and can be found on the NASDAQ under the ticker symbol IRWD. The average price purchasers were willing to pay for the shares was $12.07, and the total amount that the shares brought in was 1,339,311.34 dollars. Following the completion of the transaction, the Chief Executive Officer acquired a total of 712,440 shares of the company’s stock, each of which has a current market value of $8,599,150.80. If you follow this link, you will be taken to a document submitted to the Securities and Exchange Commission (SEC). The document contains an in-depth explanation of the reported transaction to the SEC.
The company’s most recent quarterly results report for Ironwood Pharmaceuticals (NASDAQ: IRWD) was made public and presented on November 3rd, making it available for consumption by the general public. The biopharmaceutical company reported quarterly earnings per share of $0.28, which is $0.01 higher than the consensus estimate of $0.27. The earnings were reported every quarter. In their financial statements, Ironwood Pharmaceuticals indicated that they had achieved a return on equity of 30.24% and a net margin of 39.85%. The most recent quarter’s actual revenues for the company came in at $108.64 million, which is lower than the consensus projection of $111.51 million that was used to forecast those revenues. Sell-side analysts expect Ironwood Pharmaceuticals, Inc. to generate $1.01 per share earnings during the current fiscal year.
In a separate development, on Saturday, December 17, the rating for Ironwood Pharmaceuticals was changed from “strong buy” to “buy.” Before this change, the company had been given a “strong-buy” rating. While three other analysts have given the stock a buy rating, one equity research expert suggests you maintain a neutral position even though the stock has been given a buy rating. According to the information that Bloomberg.com provided, the average rating for the company is “Moderate Buy,” and the current consensus target price is $14.67.
The price of NASDAQ IRWD dropped to $11.18 at the end of the trading day on Monday as a result of a loss of $1.38 that occurred during the session. The average stock volume is 2,064,411 shares per day, which is significantly higher than the number of shares traded today, which was 4,488,754 shares. During the last year and a half, Ironwood Pharmaceuticals, Inc.’s share price fluctuated between $9.73 and $12.95, with an average price of $12.95. The simple moving average for the stock over the past 50 days is $11.87, and the simple moving average for the past 200 days is $11.39 respectively. The company’s price-to-earnings ratio is 11.88, and its beta value is 0.96. The company is currently valued at $1.71 billion on the market. There is a debt-to-equity ratio that is equal to 0.67, a quick ratio that is equal to 25.78, a current ratio that is equal to 0.67, and a quick ratio that is equal to 0.67.
In recent months, the company’s stock market has been the focus of activity from several major investors, who have been buying and selling shares. During the third quarter, Quadrant Capital Group LLC saw a rise of 2,065.5% in the amount of Ironwood Pharmaceuticals stock that it held as a percentage of its total holdings. Following the acquisition of 3,594 additional shares during the most recent quarter, Quadrant Capital Group LLC now holds 3,768 shares of the biotechnology company’s stock. Each share of this stock is currently worth $39,000 due to recent market activity. During the second quarter of this year, Gladius Capital Management LP provided Ironwood Pharmaceuticals with an investment of $55,000. Ironwood Pharmaceuticals was the recipient of this investment. In addition, the Banque Cantonale Vaudoise increased its overall holdings in Ironwood Pharmaceuticals by making an additional investment of approximately $58,000 during the second quarter. Finally, during the second quarter, Captrust Financial Advisors made a staggering increase of 441.7% in the quantity of Ironwood Pharmaceuticals stock that it held. Captrust Financial Advisors now has a total of 6,690 shares of the biotechnology company’s stock following the purchase of an additional 5,455 shares during the most recent quarter. A cost of $77,000 was incurred to acquire these shares.
Lastly, during the first quarter of this year, Lazard Asset Management LLC purchased a new stake in Ironwood Pharmaceuticals. This new stake was valued at approximately $78,000. The company fronted the money for this investment itself.
Ironwood Pharmaceuticals, Inc. is a company that operates in the medical industry and is accountable for producing and selling medications that are used to treat conditions related to the gastrointestinal tract (GI). Linaclotide is a guanylate cyclase type-C agonist. It is sold under the brand names LINZESS in the United States and Mexico and CONSTELLA in Canada and the European Union. Linaclotide treats people who suffer from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation. Linzess is sold in the United States and Mexico. STELLA is sold in CIC.

Tags

Leave a comment

Your email address will not be published. Required fields are marked *